Elgan Pharma and Chiesi Group Start Pivotal Phase 3 Study for Preterm Infants Elgan Pharma and Chiesi Group jointly announced the initiation of a Phase 3 clinical study, ELGN-2112, targeting intestinal malabsorption in preterm infants. Aimed at improving their health outcomes, this study seeks to redefine treatments.

Elgan Pharma and Chiesi Group Start Pivotal Phase 3 Study for Preterm Infants #Israel #Nazareth #Chiesi_Group #ELGN-2112 #Elgan_Pharma